Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 28, 2026

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects
11:12

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects

Published on: September 18, 2012

Driving ability under sertindole.

A Brunnauer1, G Laux

  • 1kbo Inn-Salzach-Klinikum, Academic Hospital of Psychiatry, Psychotherapy, Psychosomatic Medicine and Neurology, Wasserburg a. Inn, Germany. Alexander.Brunnauer@iskl.de

Pharmacopsychiatry
|October 13, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same author

Prospective ECG-gated High-Pitch Photon-Counting CT Angiography: Evaluation of measurement accuracy for aortic annulus sizing in TAVR planning.

European journal of radiology·2024
Same author

Steroid Maintenance Therapy after Transplantation-Quo Vadis?: Long-Term Prospective Study of Steroid Withdrawal in Kidney and Heart Transplant Recipients. Am J Transplant 5: 720-728, 2005.

Journal of the American Society of Nephrology : JASN·2023
Same author

Effects of physical activity on cognitive performance: a controlled clinical study in depressive patients.

European archives of psychiatry and clinical neuroscience·2018
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.

Pharmacopsychiatry·2018
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.

Pharmacopsychiatry·2017
Same journal

Editorial.

Pharmacopsychiatry·2026
Same journal

A Tribute to Prof. Jules Angst highlighting his Contributions to Clozapine.

Pharmacopsychiatry·2026
Same journal

Correction: Escitalopram and Clonazepam Affect Gasotransmitter-related Enzyme (nNOS, HO-2, CBS) Gene Expression in the Rat Brain.

Pharmacopsychiatry·2026
Same journal

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same journal

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
See all related articles

Many stabilized schizophrenic patients show impaired driving skills, regardless of atypical antipsychotic treatment. This study found no significant differences in driving ability between sertindole, risperidone, and quetiapine. A substantial number remain unfit to drive.

Area of Science:

  • Psychiatry
  • Neuroscience
  • Clinical Psychology

Background:

  • Fitness to drive is crucial for functional autonomy, especially for psychiatric patients.
  • Sertindole's efficacy for schizophrenia symptoms is known, but its impact on driving ability is unstudied.
  • Antipsychotic medications can affect cognitive and psychomotor functions relevant to driving.

Purpose of the Study:

  • To assess the fitness to drive in schizophrenic patients treated with sertindole compared to risperidone and quetiapine.
  • To evaluate the impact of atypical antipsychotics on psychomotor skills essential for driving.
  • To determine if sertindole treatment affects driving ability in schizophrenia patients.

Main Methods:

  • A non-randomized clinical study involving 30 schizophrenic inpatients.

More Related Videos

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research
07:15

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research

Published on: December 18, 2020

Driving Under the Influence: How Music Listening Affects Driving Behaviors
07:25

Driving Under the Influence: How Music Listening Affects Driving Behaviors

Published on: March 27, 2019

Related Experiment Videos

Last Updated: May 28, 2026

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects
11:12

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects

Published on: September 18, 2012

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research
07:15

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research

Published on: December 18, 2020

Driving Under the Influence: How Music Listening Affects Driving Behaviors
07:25

Driving Under the Influence: How Music Listening Affects Driving Behaviors

Published on: March 27, 2019

  • Patients received sertindole (n=10), risperidone (n=10), or quetiapine (n=10) under steady-state conditions.
  • Psychomotor skills relevant to driving were assessed using the Act and React Testsystem (ART90) and Wiener Determinationsgerät (WDG).

    • Main Results:

    • Approximately 26% of stabilized schizophrenic patients exhibited severe driving skill impairments before discharge.
    • No statistically significant differences in global driving ability scores were found between the three antipsychotic groups.
    • Individual functional domains essential for driving also showed no significant differences between sertindole, risperidone, and quetiapine.

    Conclusions:

    • No significant differences in driving skills were observed among patients treated with sertindole, risperidone, or quetiapine.
    • A considerable proportion of schizophrenia patients, even when stabilized, may be unfit to drive.
    • These findings highlight the need for careful driving ability assessment in schizophrenia patients on atypical antipsychotics.